Candida auris — a fungus with attitude
Presently, in the face of the global COVID-19 pandemic, it is easy to understand that we have seen a significant shift in both awareness and practical application of improved infection prevention and control practices. The pandemic has driven advances in all aspects of disease prevention from the basics of hygiene, including hand sanitisation and surface cleaning and disinfection, to social distancing and incredible advances and acceleration of vaccine development and production.
The global nature of the virus and the enormous human toll has focussed people specifically on COVID-19, and whilst that is incredibly important in dealing with the immediate danger, we have been fighting infectious diseases with science for a very long time. It is important to note that there are still many other bacteria, viruses and fungi that need to be combatted to best protect patients, healthcare staff and the wider population against these significant dangers. If we focus just on COVID-19 and things such as disinfectant contact times and efficacy for COVID-19, we risk not suitably managing these other risks, which will lead to increased adverse health outcomes and morbidity.
Candida auris (C. auris) is a fungus from the same group of germs that cause thrush (Candida albicans) or serious blood stream infections in immune-compromised patients (C. glabrata, C. parapsilosis, C. krusei and C. tropicalis). However, unlike most of the other candida species which live in the gastrointestinal tract, this fungus is also commonly found living on the skin. It is also much more resistant than other fungi to commonly used treatments and over 90% of C. auris cases to date have been resistant to fluconazole, the standard treatment for candida infections.
Multi-resistant C. auris has only emerged relatively recently; it was first identified in Japan and South Korea in 2009 but had spread to six continents by 2017. C. auris is of particular interest to clinicians, infectious disease experts and infection prevention and control (IPC) professionals due to the following characteristics of the fungus:1
- It is a pathogen — it causes disease.
- It is of risk to all types of patients.
- It is highly virulent.
- It is often misclassified in laboratory diagnostic tests and so is missed.
- There are few treatment options.
- It spreads easily in the environment.
- It is resilient to environmental disinfection.
- It has been responsible for healthcare outbreaks.
Healthcare facility outbreaks
As with many other antimicrobial-resistant pathogens, C. auris has been implicated in many hospital outbreaks around the world. A large outbreak lasting over 12 months between 2015 and 2016 in a London cardiothoracic intensive care unit resulted in 50 cases. Contact with an environment contaminated with C. auris was found to be a significant source of infection with the fungus. Among the surfaces found to be contaminated were the floor, dressing trollies, equipment monitors and keypads, and windowsills.
Infection prevention and control measures
C. auris cases should be taken very seriously in all healthcare facilities and strict measures put in place to prevent spread to other patients.
These measures are similar to other important IPC practices for multidrug-resistant organisms and include the following key actions:
- Notify local IPC and infectious diseases experts.
- Place patient in single room with contact precautions in addition to routine practices.
- In case of symptomatic disease, begin treatment, preferably with guidance from an infectious disease specialist (treatment of asymptomatic colonisation is not recommended).
- Start contact tracing and screening to determine any local transmission.
- Focus on environmental disinfection.
Disinfection of a contaminated environment
As previously noted, removing C. auris from the environment is a challenge due to the ease in which it appears to spread and its resistance to many common cleaning agents. The environment can remain contaminated with the pathogen for weeks. Subsequently, many national and international guidelines for the management of these infections advise daily and terminal or discharge cleaning with a strong environmental disinfectant such as a sporicidal disinfectant.
As with all environmental disinfection options, success will be easier if the area is regularly cleaned so that surface biofilm is not allowed to build up. Importantly, as with other pathogens, ensuring suitable contact exposure to the disinfectant and sporicidal agent is essential in effective outcomes and pathogen reduction.
Multidrug-resistant C. auris is an important emerging pathogen which demands attention and action when identified in the healthcare setting. As well as implementing common IPC measures used for multidrug-resistant organisms, disinfection of a potentially contaminated environment must be a priority. Always follow local and national guidelines for managing this pathogen and ensure all contact times are followed completely, noting that contact times against different pathogens may vary for any disinfectant or sporicidal agent. To ensure complete effectiveness, ensure exposure for the time specified for the full spectrum of pathogens.
Schelenz, Silke, et al. “First hospital outbreak of the globally emerging Candida auris in a European hospital”. Antimicrobial Resistance & Infection Control 5.1 (2016): 35. https://aricjournal.biomedcentral.com/articles/10.1186/s13756-016-0132-5.
Schwartz, Smith & TC Dingle. “Something wicked this way comes: What health care providers need to know about Candida auris”. Can Commun Dis Rep (2018);44(11):271–6. https://doi. org/10.14745/ccdr.v44i11a014.
Queensland Health, Candida auris infection prevention and control.
The Hip Fracture Registry Toolbox is a practical and informative resource that explains the need,...
Treating high-risk patients with recommended blood pressure and cholesterol-lowering medicines...
In the washroom, Australians are most concerned about their co-workers not washing their hands,...